Public Act 100-0280
 
HB3910 EnrolledLRB100 10675 RLC 20899 b

    AN ACT concerning criminal law.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The Illinois Controlled Substances Act is
amended by changing Sections 102 and 312 as follows:
 
    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
    Sec. 102. Definitions. As used in this Act, unless the
context otherwise requires:
    (a) "Addict" means any person who habitually uses any drug,
chemical, substance or dangerous drug other than alcohol so as
to endanger the public morals, health, safety or welfare or who
is so far addicted to the use of a dangerous drug or controlled
substance other than alcohol as to have lost the power of self
control with reference to his or her addiction.
    (b) "Administer" means the direct application of a
controlled substance, whether by injection, inhalation,
ingestion, or any other means, to the body of a patient,
research subject, or animal (as defined by the Humane
Euthanasia in Animal Shelters Act) by:
        (1) a practitioner (or, in his or her presence, by his
    or her authorized agent),
        (2) the patient or research subject pursuant to an
    order, or
        (3) a euthanasia technician as defined by the Humane
    Euthanasia in Animal Shelters Act.
    (c) "Agent" means an authorized person who acts on behalf
of or at the direction of a manufacturer, distributor,
dispenser, prescriber, or practitioner. It does not include a
common or contract carrier, public warehouseman or employee of
the carrier or warehouseman.
    (c-1) "Anabolic Steroids" means any drug or hormonal
substance, chemically and pharmacologically related to
testosterone (other than estrogens, progestins,
corticosteroids, and dehydroepiandrosterone), and includes:
    (i) 3[beta],17-dihydroxy-5a-androstane, 
    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
    (iii) 5[alpha]-androstan-3,17-dione, 
    (iv) 1-androstenediol (3[beta], 
        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
    (v) 1-androstenediol (3[alpha], 
        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
    (vi) 4-androstenediol  
        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
    (vii) 5-androstenediol  
        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
    (viii) 1-androstenedione  
        ([5alpha]-androst-1-en-3,17-dione), 
    (ix) 4-androstenedione  
        (androst-4-en-3,17-dione), 
    (x) 5-androstenedione  
        (androst-5-en-3,17-dione), 
    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
        hydroxyandrost-4-en-3-one), 
    (xii) boldenone (17[beta]-hydroxyandrost- 
        1,4,-diene-3-one), 
    (xiii) boldione (androsta-1,4- 
        diene-3,17-dione), 
    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
        [beta]-hydroxyandrost-4-en-3-one), 
    (xv) clostebol (4-chloro-17[beta]- 
        hydroxyandrost-4-en-3-one), 
    (xvi) dehydrochloromethyltestosterone (4-chloro- 
        17[beta]-hydroxy-17[alpha]-methyl- 
        androst-1,4-dien-3-one), 
    (xvii) desoxymethyltestosterone 
    (17[alpha]-methyl-5[alpha] 
        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
        '1-testosterone') (17[beta]-hydroxy- 
        5[alpha]-androst-1-en-3-one), 
    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
        androstan-3-one), 
    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
        5[alpha]-androstan-3-one), 
    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
        hydroxyestr-4-ene), 
    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
        hydroxyandrostano[2,3-c]-furazan), 
    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
        androst-4-en-3-one), 
    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
        dihydroxy-estr-4-en-3-one), 
    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
        hydroxy-5-androstan-3-one), 
    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
        [5a]-androstan-3-one), 
    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
        hydroxyandrost-1,4-dien-3-one), 
    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
        dihydroxyandrost-5-ene), 
    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
        5[alpha]-androst-1-en-3-one), 
    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
        dihydroxy-5a-androstane), 
    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
        -5a-androstane), 
    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
        dihydroxyandrost-4-ene), 
    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
        hydroxyestra-4,9(10)-dien-3-one), 
    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
        hydroxyestra-4,9-11-trien-3-one), 
    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
        hydroxyandrost-4-en-3-one), 
    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
        1-testosterone'), 
    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
        dihydroxyestr-4-ene), 
    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
        dihydroxyestr-4-ene), 
    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
        dihydroxyestr-5-ene), 
    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
        dihydroxyestr-5-ene), 
    (xlvii) 19-nor-4,9(10)-androstadienedione  
        (estra-4,9(10)-diene-3,17-dione), 
    (xlviii) 19-nor-4-androstenedione (estr-4- 
        en-3,17-dione), 
    (xlix) 19-nor-5-androstenedione (estr-5- 
        en-3,17-dione), 
    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
        hydroxygon-4-en-3-one), 
    (li) norclostebol (4-chloro-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
        2-oxa-5[alpha]-androstan-3-one), 
    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
        dihydroxyandrost-4-en-3-one), 
    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
        (5[alpha]-androst-1-en-3-one), 
    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
        secoandrosta-1,4-dien-17-oic 
        acid lactone), 
    (lx) testosterone (17[beta]-hydroxyandrost- 
        4-en-3-one), 
    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
        diethyl-17[beta]-hydroxygon- 
        4,9,11-trien-3-one), 
    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
        11-trien-3-one). 
    Any person who is otherwise lawfully in possession of an
anabolic steroid, or who otherwise lawfully manufactures,
distributes, dispenses, delivers, or possesses with intent to
deliver an anabolic steroid, which anabolic steroid is
expressly intended for and lawfully allowed to be administered
through implants to livestock or other nonhuman species, and
which is approved by the Secretary of Health and Human Services
for such administration, and which the person intends to
administer or have administered through such implants, shall
not be considered to be in unauthorized possession or to
unlawfully manufacture, distribute, dispense, deliver, or
possess with intent to deliver such anabolic steroid for
purposes of this Act.
    (d) "Administration" means the Drug Enforcement
Administration, United States Department of Justice, or its
successor agency.
    (d-5) "Clinical Director, Prescription Monitoring Program"
means a Department of Human Services administrative employee
licensed to either prescribe or dispense controlled substances
who shall run the clinical aspects of the Department of Human
Services Prescription Monitoring Program and its Prescription
Information Library.
    (d-10) "Compounding" means the preparation and mixing of
components, excluding flavorings, (1) as the result of a
prescriber's prescription drug order or initiative based on the
prescriber-patient-pharmacist relationship in the course of
professional practice or (2) for the purpose of, or incident
to, research, teaching, or chemical analysis and not for sale
or dispensing. "Compounding" includes the preparation of drugs
or devices in anticipation of receiving prescription drug
orders based on routine, regularly observed dispensing
patterns. Commercially available products may be compounded
for dispensing to individual patients only if both of the
following conditions are met: (i) the commercial product is not
reasonably available from normal distribution channels in a
timely manner to meet the patient's needs and (ii) the
prescribing practitioner has requested that the drug be
compounded.
    (e) "Control" means to add a drug or other substance, or
immediate precursor, to a Schedule whether by transfer from
another Schedule or otherwise.
    (f) "Controlled Substance" means (i) a drug, substance,
immediate precursor, or synthetic drug in the Schedules of
Article II of this Act or (ii) a drug or other substance, or
immediate precursor, designated as a controlled substance by
the Department through administrative rule. The term does not
include distilled spirits, wine, malt beverages, or tobacco, as
those terms are defined or used in the Liquor Control Act of
1934 and the Tobacco Products Tax Act of 1995.
    (f-5) "Controlled substance analog" means a substance:
        (1) the chemical structure of which is substantially
    similar to the chemical structure of a controlled substance
    in Schedule I or II;
        (2) which has a stimulant, depressant, or
    hallucinogenic effect on the central nervous system that is
    substantially similar to or greater than the stimulant,
    depressant, or hallucinogenic effect on the central
    nervous system of a controlled substance in Schedule I or
    II; or
        (3) with respect to a particular person, which such
    person represents or intends to have a stimulant,
    depressant, or hallucinogenic effect on the central
    nervous system that is substantially similar to or greater
    than the stimulant, depressant, or hallucinogenic effect
    on the central nervous system of a controlled substance in
    Schedule I or II.
    (g) "Counterfeit substance" means a controlled substance,
which, or the container or labeling of which, without
authorization bears the trademark, trade name, or other
identifying mark, imprint, number or device, or any likeness
thereof, of a manufacturer, distributor, or dispenser other
than the person who in fact manufactured, distributed, or
dispensed the substance.
    (h) "Deliver" or "delivery" means the actual, constructive
or attempted transfer of possession of a controlled substance,
with or without consideration, whether or not there is an
agency relationship.
    (i) "Department" means the Illinois Department of Human
Services (as successor to the Department of Alcoholism and
Substance Abuse) or its successor agency.
    (j) (Blank).
    (k) "Department of Corrections" means the Department of
Corrections of the State of Illinois or its successor agency.
    (l) "Department of Financial and Professional Regulation"
means the Department of Financial and Professional Regulation
of the State of Illinois or its successor agency.
    (m) "Depressant" means any drug that (i) causes an overall
depression of central nervous system functions, (ii) causes
impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including
but not limited to alcohol, cannabis and its active principles
and their analogs, benzodiazepines and their analogs,
barbiturates and their analogs, opioids (natural and
synthetic) and their analogs, and chloral hydrate and similar
sedative hypnotics.
    (n) (Blank).
    (o) "Director" means the Director of the Illinois State
Police or his or her designated agents.
    (p) "Dispense" means to deliver a controlled substance to
an ultimate user or research subject by or pursuant to the
lawful order of a prescriber, including the prescribing,
administering, packaging, labeling, or compounding necessary
to prepare the substance for that delivery.
    (q) "Dispenser" means a practitioner who dispenses.
    (r) "Distribute" means to deliver, other than by
administering or dispensing, a controlled substance.
    (s) "Distributor" means a person who distributes.
    (t) "Drug" means (1) substances recognized as drugs in the
official United States Pharmacopoeia, Official Homeopathic
Pharmacopoeia of the United States, or official National
Formulary, or any supplement to any of them; (2) substances
intended for use in diagnosis, cure, mitigation, treatment, or
prevention of disease in man or animals; (3) substances (other
than food) intended to affect the structure of any function of
the body of man or animals and (4) substances intended for use
as a component of any article specified in clause (1), (2), or
(3) of this subsection. It does not include devices or their
components, parts, or accessories.
    (t-3) "Electronic health record" or "EHR" means an
electronic record of health-related information on an
individual that is created, gathered, managed, and consulted by
authorized health care clinicians and staff.
    (t-4) "Emergency medical services personnel" has the
meaning ascribed to it in the Emergency Medical Services (EMS)
Systems Act.
    (t-5) "Euthanasia agency" means an entity certified by the
Department of Financial and Professional Regulation for the
purpose of animal euthanasia that holds an animal control
facility license or animal shelter license under the Animal
Welfare Act. A euthanasia agency is authorized to purchase,
store, possess, and utilize Schedule II nonnarcotic and
Schedule III nonnarcotic drugs for the sole purpose of animal
euthanasia.
    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
substances (nonnarcotic controlled substances) that are used
by a euthanasia agency for the purpose of animal euthanasia.
    (u) "Good faith" means the prescribing or dispensing of a
controlled substance by a practitioner in the regular course of
professional treatment to or for any person who is under his or
her treatment for a pathology or condition other than that
individual's physical or psychological dependence upon or
addiction to a controlled substance, except as provided herein:
and application of the term to a pharmacist shall mean the
dispensing of a controlled substance pursuant to the
prescriber's order which in the professional judgment of the
pharmacist is lawful. The pharmacist shall be guided by
accepted professional standards including, but not limited to
the following, in making the judgment:
        (1) lack of consistency of prescriber-patient
    relationship,
        (2) frequency of prescriptions for same drug by one
    prescriber for large numbers of patients,
        (3) quantities beyond those normally prescribed,
        (4) unusual dosages (recognizing that there may be
    clinical circumstances where more or less than the usual
    dose may be used legitimately),
        (5) unusual geographic distances between patient,
    pharmacist and prescriber,
        (6) consistent prescribing of habit-forming drugs.
    (u-0.5) "Hallucinogen" means a drug that causes markedly
altered sensory perception leading to hallucinations of any
type.
    (u-1) "Home infusion services" means services provided by a
pharmacy in compounding solutions for direct administration to
a patient in a private residence, long-term care facility, or
hospice setting by means of parenteral, intravenous,
intramuscular, subcutaneous, or intraspinal infusion.
    (u-5) "Illinois State Police" means the State Police of the
State of Illinois, or its successor agency.
    (v) "Immediate precursor" means a substance:
        (1) which the Department has found to be and by rule
    designated as being a principal compound used, or produced
    primarily for use, in the manufacture of a controlled
    substance;
        (2) which is an immediate chemical intermediary used or
    likely to be used in the manufacture of such controlled
    substance; and
        (3) the control of which is necessary to prevent,
    curtail or limit the manufacture of such controlled
    substance.
    (w) "Instructional activities" means the acts of teaching,
educating or instructing by practitioners using controlled
substances within educational facilities approved by the State
Board of Education or its successor agency.
    (x) "Local authorities" means a duly organized State,
County or Municipal peace unit or police force.
    (y) "Look-alike substance" means a substance, other than a
controlled substance which (1) by overall dosage unit
appearance, including shape, color, size, markings or lack
thereof, taste, consistency, or any other identifying physical
characteristic of the substance, would lead a reasonable person
to believe that the substance is a controlled substance, or (2)
is expressly or impliedly represented to be a controlled
substance or is distributed under circumstances which would
lead a reasonable person to believe that the substance is a
controlled substance. For the purpose of determining whether
the representations made or the circumstances of the
distribution would lead a reasonable person to believe the
substance to be a controlled substance under this clause (2) of
subsection (y), the court or other authority may consider the
following factors in addition to any other factor that may be
relevant:
        (a) statements made by the owner or person in control
    of the substance concerning its nature, use or effect;
        (b) statements made to the buyer or recipient that the
    substance may be resold for profit;
        (c) whether the substance is packaged in a manner
    normally used for the illegal distribution of controlled
    substances;
        (d) whether the distribution or attempted distribution
    included an exchange of or demand for money or other
    property as consideration, and whether the amount of the
    consideration was substantially greater than the
    reasonable retail market value of the substance.
    Clause (1) of this subsection (y) shall not apply to a
noncontrolled substance in its finished dosage form that was
initially introduced into commerce prior to the initial
introduction into commerce of a controlled substance in its
finished dosage form which it may substantially resemble.
    Nothing in this subsection (y) prohibits the dispensing or
distributing of noncontrolled substances by persons authorized
to dispense and distribute controlled substances under this
Act, provided that such action would be deemed to be carried
out in good faith under subsection (u) if the substances
involved were controlled substances.
    Nothing in this subsection (y) or in this Act prohibits the
manufacture, preparation, propagation, compounding,
processing, packaging, advertising or distribution of a drug or
drugs by any person registered pursuant to Section 510 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
    (y-1) "Mail-order pharmacy" means a pharmacy that is
located in a state of the United States that delivers,
dispenses or distributes, through the United States Postal
Service or other common carrier, to Illinois residents, any
substance which requires a prescription.
    (z) "Manufacture" means the production, preparation,
propagation, compounding, conversion or processing of a
controlled substance other than methamphetamine, either
directly or indirectly, by extraction from substances of
natural origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis, and includes any packaging or repackaging of the
substance or labeling of its container, except that this term
does not include:
        (1) by an ultimate user, the preparation or compounding
    of a controlled substance for his or her own use; or
        (2) by a practitioner, or his or her authorized agent
    under his or her supervision, the preparation,
    compounding, packaging, or labeling of a controlled
    substance:
            (a) as an incident to his or her administering or
        dispensing of a controlled substance in the course of
        his or her professional practice; or
            (b) as an incident to lawful research, teaching or
        chemical analysis and not for sale.
    (z-1) (Blank).
    (z-5) "Medication shopping" means the conduct prohibited
under subsection (a) of Section 314.5 of this Act.
    (z-10) "Mid-level practitioner" means (i) a physician
assistant who has been delegated authority to prescribe through
a written delegation of authority by a physician licensed to
practice medicine in all of its branches, in accordance with
Section 7.5 of the Physician Assistant Practice Act of 1987,
(ii) an advanced practice nurse who has been delegated
authority to prescribe through a written delegation of
authority by a physician licensed to practice medicine in all
of its branches or by a podiatric physician, in accordance with
Section 65-40 of the Nurse Practice Act, (iii) an advanced
practice nurse certified as a nurse practitioner, nurse
midwife, or clinical nurse specialist who has been granted
authority to prescribe by a hospital affiliate in accordance
with Section 65-45 of the Nurse Practice Act, (iv) an animal
euthanasia agency, or (v) a prescribing psychologist.
    (aa) "Narcotic drug" means any of the following, whether
produced directly or indirectly by extraction from substances
of vegetable origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis:
        (1) opium, opiates, derivatives of opium and opiates,
    including their isomers, esters, ethers, salts, and salts
    of isomers, esters, and ethers, whenever the existence of
    such isomers, esters, ethers, and salts is possible within
    the specific chemical designation; however the term
    "narcotic drug" does not include the isoquinoline
    alkaloids of opium;
        (2) (blank);
        (3) opium poppy and poppy straw;
        (4) coca leaves, except coca leaves and extracts of
    coca leaves from which substantially all of the cocaine and
    ecgonine, and their isomers, derivatives and salts, have
    been removed;
        (5) cocaine, its salts, optical and geometric isomers,
    and salts of isomers;
        (6) ecgonine, its derivatives, their salts, isomers,
    and salts of isomers;
        (7) any compound, mixture, or preparation which
    contains any quantity of any of the substances referred to
    in subparagraphs (1) through (6).
    (bb) "Nurse" means a registered nurse licensed under the
Nurse Practice Act.
    (cc) (Blank).
    (dd) "Opiate" means any substance having an addiction
forming or addiction sustaining liability similar to morphine
or being capable of conversion into a drug having addiction
forming or addiction sustaining liability.
    (ee) "Opium poppy" means the plant of the species Papaver
somniferum L., except its seeds.
    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
solution or other liquid form of medication intended for
administration by mouth, but the term does not include a form
of medication intended for buccal, sublingual, or transmucosal
administration.
    (ff) "Parole and Pardon Board" means the Parole and Pardon
Board of the State of Illinois or its successor agency.
    (gg) "Person" means any individual, corporation,
mail-order pharmacy, government or governmental subdivision or
agency, business trust, estate, trust, partnership or
association, or any other entity.
    (hh) "Pharmacist" means any person who holds a license or
certificate of registration as a registered pharmacist, a local
registered pharmacist or a registered assistant pharmacist
under the Pharmacy Practice Act.
    (ii) "Pharmacy" means any store, ship or other place in
which pharmacy is authorized to be practiced under the Pharmacy
Practice Act.
    (ii-5) "Pharmacy shopping" means the conduct prohibited
under subsection (b) of Section 314.5 of this Act.
    (ii-10) "Physician" (except when the context otherwise
requires) means a person licensed to practice medicine in all
of its branches.
    (jj) "Poppy straw" means all parts, except the seeds, of
the opium poppy, after mowing.
    (kk) "Practitioner" means a physician licensed to practice
medicine in all its branches, dentist, optometrist, podiatric
physician, veterinarian, scientific investigator, pharmacist,
physician assistant, advanced practice nurse, licensed
practical nurse, registered nurse, emergency medical services
personnel, hospital, laboratory, or pharmacy, or other person
licensed, registered, or otherwise lawfully permitted by the
United States or this State to distribute, dispense, conduct
research with respect to, administer or use in teaching or
chemical analysis, a controlled substance in the course of
professional practice or research.
    (ll) "Pre-printed prescription" means a written
prescription upon which the designated drug has been indicated
prior to the time of issuance; the term does not mean a written
prescription that is individually generated by machine or
computer in the prescriber's office.
    (mm) "Prescriber" means a physician licensed to practice
medicine in all its branches, dentist, optometrist,
prescribing psychologist licensed under Section 4.2 of the
Clinical Psychologist Licensing Act with prescriptive
authority delegated under Section 4.3 of the Clinical
Psychologist Licensing Act, podiatric physician, or
veterinarian who issues a prescription, a physician assistant
who issues a prescription for a controlled substance in
accordance with Section 303.05, a written delegation, and a
written supervision agreement required under Section 7.5 of the
Physician Assistant Practice Act of 1987, an advanced practice
nurse with prescriptive authority delegated under Section
65-40 of the Nurse Practice Act and in accordance with Section
303.05, a written delegation, and a written collaborative
agreement under Section 65-35 of the Nurse Practice Act, or an
advanced practice nurse certified as a nurse practitioner,
nurse midwife, or clinical nurse specialist who has been
granted authority to prescribe by a hospital affiliate in
accordance with Section 65-45 of the Nurse Practice Act and in
accordance with Section 303.05.
    (nn) "Prescription" means a written, facsimile, or oral
order, or an electronic order that complies with applicable
federal requirements, of a physician licensed to practice
medicine in all its branches, dentist, podiatric physician or
veterinarian for any controlled substance, of an optometrist in
accordance with Section 15.1 of the Illinois Optometric
Practice Act of 1987, of a prescribing psychologist licensed
under Section 4.2 of the Clinical Psychologist Licensing Act
with prescriptive authority delegated under Section 4.3 of the
Clinical Psychologist Licensing Act, of a physician assistant
for a controlled substance in accordance with Section 303.05, a
written delegation, and a written supervision agreement
required under Section 7.5 of the Physician Assistant Practice
Act of 1987, of an advanced practice nurse with prescriptive
authority delegated under Section 65-40 of the Nurse Practice
Act who issues a prescription for a controlled substance in
accordance with Section 303.05, a written delegation, and a
written collaborative agreement under Section 65-35 of the
Nurse Practice Act, or of an advanced practice nurse certified
as a nurse practitioner, nurse midwife, or clinical nurse
specialist who has been granted authority to prescribe by a
hospital affiliate in accordance with Section 65-45 of the
Nurse Practice Act and in accordance with Section 303.05 when
required by law.
    (nn-5) "Prescription Information Library" (PIL) means an
electronic library that contains reported controlled substance
data.
    (nn-10) "Prescription Monitoring Program" (PMP) means the
entity that collects, tracks, and stores reported data on
controlled substances and select drugs pursuant to Section 316.
    (oo) "Production" or "produce" means manufacture,
planting, cultivating, growing, or harvesting of a controlled
substance other than methamphetamine.
    (pp) "Registrant" means every person who is required to
register under Section 302 of this Act.
    (qq) "Registry number" means the number assigned to each
person authorized to handle controlled substances under the
laws of the United States and of this State.
    (qq-5) "Secretary" means, as the context requires, either
the Secretary of the Department or the Secretary of the
Department of Financial and Professional Regulation, and the
Secretary's designated agents.
    (rr) "State" includes the State of Illinois and any state,
district, commonwealth, territory, insular possession thereof,
and any area subject to the legal authority of the United
States of America.
    (rr-5) "Stimulant" means any drug that (i) causes an
overall excitation of central nervous system functions, (ii)
causes impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including
but not limited to amphetamines and their analogs,
methylphenidate and its analogs, cocaine, and phencyclidine
and its analogs.
    (ss) "Ultimate user" means a person who lawfully possesses
a controlled substance for his or her own use or for the use of
a member of his or her household or for administering to an
animal owned by him or her or by a member of his or her
household.
(Source: P.A. 98-214, eff. 8-9-13; 98-668, eff. 6-25-14;
98-756, eff. 7-16-14; 98-1111, eff. 8-26-14; 99-78, eff.
7-20-15; 99-173, eff. 7-29-15; 99-371, eff. 1-1-16; 99-480,
eff. 9-9-15; 99-642, eff. 7-28-16.)
 
    (720 ILCS 570/312)  (from Ch. 56 1/2, par. 1312)
    Sec. 312. Requirements for dispensing controlled
substances.
    (a) A practitioner, in good faith, may dispense a Schedule
II controlled substance, which is a narcotic drug listed in
Section 206 of this Act; or which contains any quantity of
amphetamine or methamphetamine, their salts, optical isomers
or salts of optical isomers; phenmetrazine and its salts; or
pentazocine; and Schedule III, IV, or V controlled substances
to any person upon a written or electronic prescription of any
prescriber, dated and signed by the person prescribing (or
electronically validated in compliance with Section 311.5) on
the day when issued and bearing the name and address of the
patient for whom, or the owner of the animal for which the
controlled substance is dispensed, and the full name, address
and registry number under the laws of the United States
relating to controlled substances of the prescriber, if he or
she is required by those laws to be registered. If the
prescription is for an animal it shall state the species of
animal for which it is ordered. The practitioner filling the
prescription shall, unless otherwise permitted, write the date
of filling and his or her own signature on the face of the
written prescription or, alternatively, shall indicate such
filling using a unique identifier as defined in paragraph (v)
of Section 3 of the Pharmacy Practice Act. The written
prescription shall be retained on file by the practitioner who
filled it or pharmacy in which the prescription was filled for
a period of 2 years, so as to be readily accessible for
inspection or removal by any officer or employee engaged in the
enforcement of this Act. Whenever the practitioner's or
pharmacy's copy of any prescription is removed by an officer or
employee engaged in the enforcement of this Act, for the
purpose of investigation or as evidence, such officer or
employee shall give to the practitioner or pharmacy a receipt
in lieu thereof. If the specific prescription is machine or
computer generated and printed at the prescriber's office, the
date does not need to be handwritten. A prescription for a
Schedule II controlled substance shall not be issued for more
than a 30 day supply, except as provided in subsection (a-5),
and shall be valid for up to 90 days after the date of
issuance. A written prescription for Schedule III, IV or V
controlled substances shall not be filled or refilled more than
6 months after the date thereof or refilled more than 5 times
unless renewed, in writing, by the prescriber. A pharmacy shall
maintain a policy regarding the type of identification
necessary, if any, to receive a prescription in accordance with
State and federal law. The pharmacy must post such information
where prescriptions are filled.
    (a-5) Physicians may issue multiple prescriptions (3
sequential 30-day supplies) for the same Schedule II controlled
substance, authorizing up to a 90-day supply. Before
authorizing a 90-day supply of a Schedule II controlled
substance, the physician must meet the following conditions:
        (1) Each separate prescription must be issued for a
    legitimate medical purpose by an individual physician
    acting in the usual course of professional practice.
        (2) The individual physician must provide written
    instructions on each prescription (other than the first
    prescription, if the prescribing physician intends for the
    prescription to be filled immediately) indicating the
    earliest date on which a pharmacy may fill that
    prescription.
        (3) The physician shall document in the medical record
    of a patient the medical necessity for the amount and
    duration of the 3 sequential 30-day prescriptions for
    Schedule II narcotics.
    (b) In lieu of a written prescription required by this
Section, a pharmacist, in good faith, may dispense Schedule
III, IV, or V substances to any person either upon receiving a
facsimile of a written, signed prescription transmitted by the
prescriber or the prescriber's agent or upon a lawful oral
prescription of a prescriber which oral prescription shall be
reduced promptly to writing by the pharmacist and such written
memorandum thereof shall be dated on the day when such oral
prescription is received by the pharmacist and shall bear the
full name and address of the ultimate user for whom, or of the
owner of the animal for which the controlled substance is
dispensed, and the full name, address, and registry number
under the law of the United States relating to controlled
substances of the prescriber prescribing if he or she is
required by those laws to be so registered, and the pharmacist
filling such oral prescription shall write the date of filling
and his or her own signature on the face of such written
memorandum thereof. The facsimile copy of the prescription or
written memorandum of the oral prescription shall be retained
on file by the proprietor of the pharmacy in which it is filled
for a period of not less than two years, so as to be readily
accessible for inspection by any officer or employee engaged in
the enforcement of this Act in the same manner as a written
prescription. The facsimile copy of the prescription or oral
prescription and the written memorandum thereof shall not be
filled or refilled more than 6 months after the date thereof or
be refilled more than 5 times, unless renewed, in writing, by
the prescriber.
    (c) Except for any non-prescription targeted
methamphetamine precursor regulated by the Methamphetamine
Precursor Control Act, a controlled substance included in
Schedule V shall not be distributed or dispensed other than for
a medical purpose and not for the purpose of evading this Act,
and then:
        (1) only personally by a person registered to dispense
    a Schedule V controlled substance and then only to his or
    her patients, or
        (2) only personally by a pharmacist, and then only to a
    person over 21 years of age who has identified himself or
    herself to the pharmacist by means of 2 positive documents
    of identification.
        (3) the dispenser shall record the name and address of
    the purchaser, the name and quantity of the product, the
    date and time of the sale, and the dispenser's signature.
        (4) no person shall purchase or be dispensed more than
    120 milliliters or more than 120 grams of any Schedule V
    substance which contains codeine, dihydrocodeine, or any
    salts thereof, or ethylmorphine, or any salts thereof, in
    any 96 hour period. The purchaser shall sign a form,
    approved by the Department of Financial and Professional
    Regulation, attesting that he or she has not purchased any
    Schedule V controlled substances within the immediately
    preceding 96 hours.
        (5) (Blank).
        (6) all records of purchases and sales shall be
    maintained for not less than 2 years.
        (7) no person shall obtain or attempt to obtain within
    any consecutive 96 hour period any Schedule V substances of
    more than 120 milliliters or more than 120 grams containing
    codeine, dihydrocodeine or any of its salts, or
    ethylmorphine or any of its salts. Any person obtaining any
    such preparations or combination of preparations in excess
    of this limitation shall be in unlawful possession of such
    controlled substance.
        (8) a person qualified to dispense controlled
    substances under this Act and registered thereunder shall
    at no time maintain or keep in stock a quantity of Schedule
    V controlled substances in excess of 4.5 liters for each
    substance; a pharmacy shall at no time maintain or keep in
    stock a quantity of Schedule V controlled substances as
    defined in excess of 4.5 liters for each substance, plus
    the additional quantity of controlled substances necessary
    to fill the largest number of prescription orders filled by
    that pharmacy for such controlled substances in any one
    week in the previous year. These limitations shall not
    apply to Schedule V controlled substances which Federal law
    prohibits from being dispensed without a prescription.
        (9) no person shall distribute or dispense butyl
    nitrite for inhalation or other introduction into the human
    body for euphoric or physical effect.
    (d) Every practitioner shall keep a record or log of
controlled substances received by him or her and a record of
all such controlled substances administered, dispensed or
professionally used by him or her otherwise than by
prescription. It shall, however, be sufficient compliance with
this paragraph if any practitioner utilizing controlled
substances listed in Schedules III, IV and V shall keep a
record of all those substances dispensed and distributed by him
or her other than those controlled substances which are
administered by the direct application of a controlled
substance, whether by injection, inhalation, ingestion, or any
other means to the body of a patient or research subject. A
practitioner who dispenses, other than by administering, a
controlled substance in Schedule II, which is a narcotic drug
listed in Section 206 of this Act, or which contains any
quantity of amphetamine or methamphetamine, their salts,
optical isomers or salts of optical isomers, pentazocine, or
methaqualone shall do so only upon the issuance of a written
prescription blank or electronic prescription issued by a
prescriber.
    (e) Whenever a manufacturer distributes a controlled
substance in a package prepared by him or her, and whenever a
wholesale distributor distributes a controlled substance in a
package prepared by him or her or the manufacturer, he or she
shall securely affix to each package in which that substance is
contained a label showing in legible English the name and
address of the manufacturer, the distributor and the quantity,
kind and form of controlled substance contained therein. No
person except a pharmacist and only for the purposes of filling
a prescription under this Act, shall alter, deface or remove
any label so affixed.
    (f) Whenever a practitioner dispenses any controlled
substance except a non-prescription Schedule V product or a
non-prescription targeted methamphetamine precursor regulated
by the Methamphetamine Precursor Control Act, he or she shall
affix to the container in which such substance is sold or
dispensed, a label indicating the date of initial filling, the
practitioner's name and address, the name of the patient, the
name of the prescriber, the directions for use and cautionary
statements, if any, contained in any prescription or required
by law, the proprietary name or names or the established name
of the controlled substance, and the dosage and quantity,
except as otherwise authorized by regulation by the Department
of Financial and Professional Regulation. No person shall
alter, deface or remove any label so affixed as long as the
specific medication remains in the container.
    (g) A person to whom or for whose use any controlled
substance has been prescribed or dispensed by a practitioner,
or other persons authorized under this Act, and the owner of
any animal for which such substance has been prescribed or
dispensed by a veterinarian, may lawfully possess such
substance only in the container in which it was delivered to
him or her by the person dispensing such substance.
    (h) The responsibility for the proper prescribing or
dispensing of controlled substances that are under the
prescriber's direct control is upon the prescriber. The
responsibility for the proper filling of a prescription for
controlled substance drugs rests with the pharmacist. An order
purporting to be a prescription issued to any individual, which
is not in the regular course of professional treatment nor part
of an authorized methadone maintenance program, nor in
legitimate and authorized research instituted by any
accredited hospital, educational institution, charitable
foundation, or federal, state or local governmental agency, and
which is intended to provide that individual with controlled
substances sufficient to maintain that individual's or any
other individual's physical or psychological addiction,
habitual or customary use, dependence, or diversion of that
controlled substance is not a prescription within the meaning
and intent of this Act; and the person issuing it, shall be
subject to the penalties provided for violations of the law
relating to controlled substances.
    (i) A prescriber shall not pre-print or cause to be
pre-printed a prescription for any controlled substance; nor
shall any practitioner issue, fill or cause to be issued or
filled, a pre-printed prescription for any controlled
substance.
    (i-5) A prescriber may use a machine or electronic device
to individually generate a printed prescription, but the
prescriber is still required to affix his or her manual
signature.
    (j) No person shall manufacture, dispense, deliver,
possess with intent to deliver, prescribe, or administer or
cause to be administered under his or her direction any
anabolic steroid, for any use in humans other than the
treatment of disease in accordance with the order of a
physician licensed to practice medicine in all its branches for
a valid medical purpose in the course of professional practice.
The use of anabolic steroids for the purpose of hormonal
manipulation that is intended to increase muscle mass, strength
or weight without a medical necessity to do so, or for the
intended purpose of improving physical appearance or
performance in any form of exercise, sport, or game, is not a
valid medical purpose or in the course of professional
practice.
    (k) Controlled substances may be mailed if all of the
following conditions are met:
        (1) The controlled substances are not outwardly
    dangerous and are not likely, of their own force, to cause
    injury to a person's life or health.
        (2) The inner container of a parcel containing
    controlled substances must be marked and sealed as required
    under this Act and its rules, and be placed in a plain
    outer container or securely wrapped in plain paper.
        (3) If the controlled substances consist of
    prescription medicines, the inner container must be
    labeled to show the name and address of the pharmacy or
    practitioner dispensing the prescription.
        (4) The outside wrapper or container must be free of
    markings that would indicate the nature of the contents.
    (l) Notwithstanding any other provision of this Act to the
contrary, emergency medical services personnel may administer
Schedule II, III, IV, or V controlled substances to a person in
the scope of their employment without a written, electronic, or
oral prescription of a prescriber.
(Source: P.A. 99-78, eff. 7-20-15; 99-480, eff. 9-9-15.)